Protective effects of cyclooxygenase-2 gene inactivation against peripheral nerve dysfunction and intraepidermal

Aaron P Kellogg1, Tim D Wiggin, Dennis D Larkin

  • 1University of Michigan, Department of Internal Medicine, 5570D MSRB II, 1150 W. Medical Center Dr., Ann Arbor, MI 48109, USA.

Diabetes
|August 28, 2007
PubMed
Abstract

Insights

Inhibition of cyclooxygenase-2 (COX-2) protects against diabetic peripheral neuropathy (DPN) by reducing nerve fiber loss and dysfunction. This suggests COX-2 inhibition may prevent or delay DPN development.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Diabetology

Background:

  • Diabetic peripheral neuropathy (DPN) involves cyclooxygenase (COX) pathway activation, neurovascular deficits, oxidative stress, and inflammation.
  • Hyperglycemia exacerbates DPN pathogenesis through these pathways.

Purpose of the Study:

  • To investigate the link between hyperglycemia, COX-2 activation, oxidative stress, and inflammation in DPN.
  • To determine if COX-2 gene inactivation protects against nerve fiber loss in long-term experimental diabetes.

Main Methods:

  • Comparison of control, diabetic wild-type (COX-2(+/+)), and diabetic COX-2-deficient (COX-2(-/-)) mice after 6 months.
  • Assessment of nerve conduction, oxidative stress, inflammation, and intraepidermal nerve fiber (IENF) density.
  • Evaluation of celecoxib (selective COX-2 inhibitor) effects in diabetic rats.

Main Results:

  • Diabetic COX-2(+/+) mice showed significant nerve dysfunction, reduced IENF density, and increased oxidative stress/inflammation.
  • Diabetic COX-2(-/-) mice were protected from DPN deficits and nerve fiber loss.
  • Selective COX-2 inhibition in diabetic rats mirrored these protective effects.

Conclusions:

  • Data indicate that COX-2 plays a critical role in the development of experimental DPN.
  • Selective COX-2 inhibition shows potential for preventing or delaying DPN.

Related Concept Videos

Diabetic Neuropathy01:22

Diabetic Neuropathy

DefinitionDiabetic neuropathy is nerve damage caused by long-standing diabetes mellitus. It results directly from prolonged high blood sugar levels.PathophysiologyThe pathophysiology of diabetic neuropathy involves both metabolic and vascular disturbances triggered by chronic hyperglycemia.Metabolic injury: Elevated glucose levels activate the polyol pathway within nerve cells, leading to the accumulation of sorbitol and fructose. This increases oxidative stress, disrupts normal nerve...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...